FTRACK
20.4.2022 18:32:06 CEST | Business Wire | Press release
ftrack , the developer of Academy Award-winning media review and team collaboration solutions for the creative industries, has launched significant updates to two of its flagship offerings: ftrack Review , the browser-based platform for interactive media review, and cineSync , the desktop media review solution heavily utilized by the film and television industries. ftrack Review’s new free-flowing user experience makes for a more lightweight, accessible media review experience for creatives, while cineSync’s fundamental update addresses the evolving needs of VFX studios working today.
Both ftrack Review’s reimagined workflows and cineSync 5 are available to try today. cineSync 5 is available as a free extension for all cineSync 4 Pro users.
ftrack was recently acquired by Backlight, a media technology company serving media, entertainment and video-forward customers with technology solutions that dramatically improve every step of the media content lifecycle. The acquisition allows ftrack to focus on product development and innovation, and provide its customers with the best possible tools and solutions like ftrack Review and cineSync.
ftrack Review Reimagined
ftrack Review introduces a newly updated, modern user interface designed for highly intuitive, user-friendly review sessions, alongside a greater focus on efficiency.
“We’ve listened to our customers’ feedback and have incorporated it into a new ftrack Review update that makes for a more responsive media review experience,” says Rory McGregor, product manager. “Users can now benefit from everything they enjoyed before—including centralized feedback cycles and interactive real-time review—but with the added advantage of a much more effortless workflow. We’re excited to see what our users think as we advance our multifaceted media review ecosystem at ftrack.”
Some of the new features in ftrack Review include:
- An all-new interface designed to make reviews more free-flowing
- Faster, more streamlined and responsive reviews with fewer clicks, even when reviewing larger projects with lots of guests and notes
- A newly designed feedback bar
- New toolbar features like ghosting, flip and flop, and resolution selection
- New features for the power user, including tools to manage reviews from within the player interface.
See the complete list of features in ftrack Review’s latest update
ftrack Review's new features are planned to be implemented into ftrack Studio soon—ftrack's full production tracking, shot management, and media review platform
"The latest update to ftrack Review shows that ftrack has listened to our needs and quickly implemented much-valued new features,” says John Valentine, ftrack/workflow coordinator at Blue Zoo Animation Studio, an animation studio known for producing children's television series, advertising commercials, and short films. “With a new, user-friendly UI, an intuitive design layout, and more emphasis on what's being reviewed, it has never been easier for ourselves or our clients to view, comment and review material, we at Blue Zoo are excited by what we've seen and what's coming next."
Introducing cineSync 5
cineSync 5 is built on the legacy of industry-leading cineSync, now reimagined and rebuilt from the ground up to meet the evolving demands of creative review and approval. cineSync 5 streamlines the media review process and supports more collaborative reviews—both local and remote—while still meeting the highest requirements across security and performance that cineSync users have come to expect over the last 17 years.
Some of the new features in cineSync 5 include:
- A new infrastructure designed to support faster, more responsive reviews
- Local review without a license via cineSync Play
- OTIO and OCIO v2 support
- Frame/image sequence playback and OpenEXR support
- Enhanced production tracking integrations with ftrack Studio and ShotGrid
- Localization support
- A new, modern UI
See the complete list of features in cineSync 5
“We’re excited to share cineSync 5 with our cineSync Pro users so they can get a first taste of the future of cineSync,” says Rory McGregor, product manager. “We’ve improved performance, added new features and workflows, updated our sync servers, and redesigned the UI. With these new features, we’re ushering in a new generation for cineSync—one that will make our users’ collaborative workflows more productive than ever before.”
“cineSync 5 is a significant upgrade on an application that's already the best in class. The killer news was the totally overhauled comparison tool with single-key access to shots, interactive and customizable wipe-line, and 0-100% cross-fades,” said Jake Morrison, VFX supervisor, Thor Love & Thunder . “Bonus points for being able to drag anywhere in the window to scrub back and forth with just a hotkey. I never knew I needed it, but now I use it all the time! Congrats to the cineSync team for an outstanding update to an already indispensable tool. They've clearly listened to their users – every new feature feels like it adds functionality. Grab it!”
Ftrack will showcase cineSync5 and the new ftrack Review later this month at the NAB Show in Las Vegas from April 23 to April 27.
About ftrack
ftrack, a Backlight business, is the creator of ftrack Studio, cineSync, and ftrack Review, the Emmy and Academy Award-winning production tracking, interactive media review, and team collaboration platforms for the creative industries. ftrack’s solutions are designed for producers, supervisors, artists, and pipeline developers and make it easy to seamlessly and securely collaborate with anyone, anywhere. Both ftrack's products and company ethos are founded on the core belief that success results from great teamwork. ftrack has built a talented global team that works with honesty, flexibility, and inclusivity and seeks to build a future where process disappears behind progress. ftrack was founded in 2012 and acquired by Backlight in 2021. ftrack is celebrating its 10th anniversary in 2022. To learn how ftrack is helping creatives meet the ever-increasing demands of creative workflows, please visit ftrack.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20220420005361/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release
Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release
The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global
IMPACT Therapeutics and Pharmanovia Announce Positive CHMP Opinion for Senaparib, as a Potential First-Line Maintenance Treatment of Advanced High-Grade Epithelial Ovarian, Fallopian Tube, and Primary Peritoneal Cancer18.9.2026 12:38:00 CEST | Press release
For business and medical media only This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918325771/en/ Stephan Eder, CEO, Pharmanovia IMPACT Therapeutics (07630.HK), a commercial-stage biotechnology company focused on the discovery and development of targeted anti-cancer therapeutics based on synthetic lethality mechanisms, together with global specialty pharmaceutical company Pharmanovia, today jointly announce that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending the granting of a Marketing Authorisation (MA) for the medicinal product Sepalna® (senaparib) intended for the maintenance treatment of advance epithelial ovarian, fallopian tube and primary peritoneal cancer. Following the CHMP’s recommendation for approval, senaparib will be submitted to the European Commission (EC) for final decision. Once approved by the EC, senaparib will
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom